الصفحة 1
الصفحة 1
Human antibody therapeutics for viral disease
The articles in this volume are definitive and comprehensive reviews written by experts who have sought to define the principles of viral neutralization by human antibodies. They explore and anticipate the obstacles and opportunities that will be encountered as the power of human antibodies is harnessed to address the vast, un-met need for effective anti-viral therapeutics.
Hepatitis C virus-host interactions and therapeutics : Current insights and future perspectives
The burden of hepatitis C virus (HCV) infection on the public health care system continues to remain significant despite the remarkable progress made in HCV therapeutics in the recent past. There are now almost a dozen oral interferon-free direct-acting antivirals available for the treatment of hepatitis C virus infection. Despite advances in the treatment of HCV, therapeutic gaps remain that are yet to be fully explored. Researchers and scientists still strive to understand virus-host interactions to map the disease’s progression along with extrahepatic manifestations and virus invasion strategies impacting the host’s immune system. This book briefly discusses the biology of HCV infection, virus-host interactions, molecular epidemiology of the infection, and the full spectrum of immune responses to hepatitis C. It also provides in-depth information about HCV, clinical diagnostics, and therapeutic knowledge to all stakeholders involved in HCV screening, diagnosis, treatment, and management.
Hepatitis C Virus Disease
Emphasizes the most recent advances on the Hepatitis C virus infection (HCV) moving from basic research to clinical application. In spite of the numerous studies on HCV infection, its pathogenesis and medical treatment have not been fully explained. The first chapters of this volume analyize the full spectrum of immune responses to HCV taking into account either innate or adoptive immunity involvement. The volume also includes a series of contributions which explain the state of art of IFN-alpha treatment in HCV patients and the effectiveness of therapy also in relation to HCV genotypes. The use and applications of pegylated IFNs will also be discussed as well as the complicated HCV disease and its treatment. Hepatitis C Virus Disease: Immunobiology and Clinical Applications is an ideal volume for researchers, scientists, professionals, clinicians, physicians and graduate students in the fields of infectious disease, immunology, virology, microbiology, pharmacology and medicine.
Drug interactions in infectious diseases : Antimicrobial drug interactions
Delivers a quick clinical resource that distills relevant drug interactions by antimicrobial drug class. The book provides informative tables on specific drug-drug interactions that include the degree and severity of the expected interaction. A mechanistic basis for drug-drug interactions is also provided to link observed interactions to pharmacologic characteristics of key drug classes. This complete resource is organized by major antibacterial, antimycobacterial, antiviral, antifungal, antimalarial, and antiprotozoal class. In line with current innovations in antimicrobial drug development, a distinct chapter on the pharmacologic management of drug interactions in hepatitis B virus (HBV) and hepatitis C virus (HCV)-related infections is included. Two new chapters are dedicated to the management of human immunodeficiency virus (HIV) drug-drug interactions given the breadth of antiretroviral class-specific effects. This comprehensive review of known drug interactions and strategies to manage them is an invaluable resource to all health care practitioners.
